Xilio Therapeutics, Inc. Operating Expenses
Xilio Therapeutics, Inc. (XLO) reported Operating Expenses of $22.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Xilio Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $22.18M, a 1.19% decline year-over-year.
- Xilio Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $26.76M, a 59.47% increase year-over-year.
- Xilio Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $25.52M, a 66.23% increase year-over-year.
- Xilio Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $21.00M, a 23.32% increase year-over-year.
- Xilio Therapeutics, Inc. operating expenses for fiscal 2025 was $85.75M, a 28.12% increase from fiscal 2024.
- Xilio Therapeutics, Inc. operating expenses for fiscal 2024 was $66.93M, a 15.43% decline from fiscal 2023.
- Xilio Therapeutics, Inc. operating expenses for fiscal 2023 was $79.13M, a 11.24% decline from fiscal 2022.
- Xilio Therapeutics, Inc. operating expenses for fiscal 2022 was $89.15M, a 18.80% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.18M 10-Q · filed 2026-08-12 | $48.94M 10-Q · filed 2026-08-12 | $74.47M derived: sum of 3 quarters · filed 2026-08-12 | $95.46M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $26.76M 10-Q · filed 2026-05-12 | $52.28M derived: sum of 2 quarters · filed 2026-05-12 | $73.28M derived: sum of 3 quarters · filed 2026-05-12 | $95.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $25.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $46.52M derived: sum of 2 quarters · filed 2026-03-23 | $68.97M derived: sum of 3 quarters · filed 2026-08-12 | $85.75M 10-K · filed 2026-03-23 |
| 2025-09-30 | $21.00M 10-Q · filed 2025-11-13 | $43.45M derived: sum of 2 quarters · filed 2026-08-12 | $60.23M 10-Q · filed 2025-11-13 | $75.58M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $22.45M 10-Q · filed 2026-08-12 | $39.23M 10-Q · filed 2026-08-12 | $54.58M derived: sum of 3 quarters · filed 2026-08-12 | $71.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $16.78M 10-Q · filed 2026-05-12 | $32.13M derived: sum of 2 quarters · filed 2026-05-12 | $49.16M derived: sum of 3 quarters · filed 2026-05-12 | $66.22M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $15.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $32.38M derived: sum of 2 quarters · filed 2026-03-23 | $49.44M derived: sum of 3 quarters · filed 2026-03-23 | $66.93M 10-K · filed 2026-03-23 |
| 2024-09-30 | $17.02M 10-Q · filed 2025-11-13 | $34.09M derived: sum of 2 quarters · filed 2025-11-13 | $51.57M 10-Q · filed 2025-11-13 | $69.70M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $17.06M 10-Q · filed 2025-08-14 | $34.55M 10-Q · filed 2025-08-14 | $52.68M derived: sum of 3 quarters · filed 2025-08-14 | $70.04M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $17.49M 10-Q · filed 2025-05-08 | $35.62M derived: sum of 2 quarters · filed 2025-05-08 | $52.98M derived: sum of 3 quarters · filed 2025-05-08 | $73.09M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $18.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $35.49M derived: sum of 2 quarters · filed 2025-03-11 | $55.61M derived: sum of 3 quarters · filed 2025-03-11 | $79.13M 10-K · filed 2025-03-11 |
| 2023-09-30 | $17.36M 10-Q · filed 2024-11-07 | $37.48M derived: sum of 2 quarters · filed 2024-11-07 | $61.00M 10-Q · filed 2024-11-07 | $84.17M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $20.12M 10-Q · filed 2024-08-08 | $43.64M 10-Q · filed 2024-08-08 | $66.81M derived: sum of 3 quarters · filed 2024-08-08 | $87.02M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $23.53M 10-Q · filed 2024-05-14 | $46.69M derived: sum of 2 quarters · filed 2024-05-14 | $66.90M derived: sum of 3 quarters · filed 2024-05-14 | $91.45M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $23.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $43.37M derived: sum of 2 quarters · filed 2024-04-01 | $67.92M derived: sum of 3 quarters · filed 2024-04-01 | $89.15M 10-K · filed 2024-04-01 |
| 2022-09-30 | $20.21M 10-Q · filed 2023-11-09 | $44.76M derived: sum of 2 quarters · filed 2023-11-09 | $65.98M 10-Q · filed 2023-11-09 | $85.54M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $24.55M 10-Q · filed 2023-08-14 | $45.78M 10-Q · filed 2023-08-14 | $65.33M derived: sum of 3 quarters · filed 2023-08-14 | $81.29M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $21.22M 10-Q · filed 2023-05-09 | $40.78M derived: sum of 2 quarters · filed 2023-05-09 | $56.74M derived: sum of 3 quarters · filed 2023-05-09 | $79.75M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $19.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $35.52M derived: sum of 2 quarters · filed 2023-03-02 | $58.52M derived: sum of 3 quarters · filed 2023-03-02 | $75.04M 10-K · filed 2023-03-02 |
| 2021-09-30 | $15.96M 10-Q · filed 2022-11-09 | $38.97M derived: sum of 2 quarters · filed 2022-11-09 | $55.49M 10-Q · filed 2022-11-09 | $76.08M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $23.01M 10-Q · filed 2022-08-09 | $39.53M 10-Q · filed 2022-08-09 | $60.12M derived: sum of 3 quarters · filed 2022-08-09 | $74.75M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $16.52M 10-Q · filed 2022-05-12 | $37.12M derived: sum of 2 quarters · filed 2022-05-12 | $51.74M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $20.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $35.22M derived: sum of 2 quarters · filed 2022-03-01 | $54.56M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $14.62M 10-Q · filed 2021-12-02 | $33.97M 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |